IP Library Patent Application 17870855
Patent Application
App. No. 17/870,855

INHIBITING DIHYDROFOLATE REDUCTASE IN A MICROORGANISM

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/870,855
Abstract

The present invention can inhibit dihydrofolate reductase in a microorganism. In some aspects, it may also suppress pigment formation in gram negative bacteria. The suppression of pigment formation can also mediate virulence suppression on other Gram negative bacteria. As such, the compounds may be used for microbial infections. The compounds can potentiate the effects of one or more antimicrobial agents when co-administered. Compositions including the compounds are provided. The composition can further include at least one antibiotic.

Claims (22)

1 . A composition for inhibiting dihydrofolate reductase in a microorganism including a compound represented by Formula I

wherein X and Y are independently O, S, or NR 10;

wherein Z is O, S, CR 11 R 12, or NR 13;

wherein R 1, R 2, R 9, R 10, R 11, R 12, R 13, and R 15, are independently absent, hydrogen, —C(O)R 18, —C(W)NRi 9 R 20, or substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aroxy, arylalkyl, heteroalkyl, alkylaryl, halogen, alkylheteroaryl, —NR 16 R 17;

wherein R 14 is independently absent, —C(W)NR 19 R 20, or substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, aroxy, arylalkyl, heteroalkyl, alkylaryl, halogen, alkylheteroaryl, —NR 16 R 17;

wherein R 16 and R 17 are independently hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, arylalkyl, heteroalkyl, alkylaryl, or alkylheteroaryl;

wherein R 18 is hydrogen, hydroxyl, or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, heterocyclyl, cycloalkenyl, heterocycloalkenyl, aryl, aroxy, heteroaryl, arylalkyl, heteroalkyl, alkylaryl, or alkylheteroaryl;

wherein W is O, S, or NR 21;

wherein R 19, R 20, and R 21 are independently hydrogen or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, arylalkyl, heteroalkyl, alkylaryl, or alkylheteroaryl;

wherein A is a double bond or single bond; and

wherein R 15 is absent when A is a double bond,

2 . The composition of claim 1 , wherein the compound is

wherein R 1 is —O—R 4, —NR 5 R 8, or —CH 2 —R 5; R 2 is halogen, absent, —O—CH 3, or —O—CH 2 —CH 3 ; R 9 is —COOH, —CH 2 —COOH, —CH 2 —O—CH 3, or —CH 2 —CH 2 —O—CH 3; R 4 is —CH 2 —R 5 or —CO—R 5; R 5 is

R 6 is a halogen or absent; and R 7 is halogen or absent.

3 . The composition of claim 2 , wherein R 1 is at a position selected from the group consisting of 2, 3, 4, 5, and 6; R 6 is at position 4; R 7 is at position 2 or 6 and R 2 is at position 3, 4, or 5.

4 . The composition of claim 2 wherein the compound is

wherein R 1 is —O—R 4, —NR 5 R 8, or —CH 2 —R 5; R 2 is halogen, absent, —O—CH 3, or —O—CH 2 —CH 3 ; R 3 is —COOH or —CH 2 —COOH; R 4 is —CH 2 —R 5 or —CO—R 5; R 5 is

R 6 is halogen or absent; and R 7 is halogen or absent.

5 . The composition of claim 4 , wherein R 1 is at a position selected from the group consisting of 2, 3, 4, 5, and 6; R 6 is at position 4; R 7 is at position 2 or 6; and R 2 is at position 3, 4, or 5.

6 . The composition of claim 1 , wherein the compound is selected from the group consisting of compounds 2 - 4 , 6 - 7 , 10 , 13 , 15 , 17 - 20 , 22 , 24 - 25 , 27 - 31 , 34 - 37 , 42 , 44 , 48 - 50 , 52 - 53 , 56 , 60 , 62 - 63 , 69 , 80 - 82 , and 87 .

7 . The composition of claim 6 , further comprising an antibiotic.

8 . The composition of claim 7 , wherein the antibiotic is selected from the group consisting of gentamicin, amikacin, kanamycin, neomycin, spectinomycin, neamine and combinations thereof.

Assignments (2)
CHANGE OF NAME Recorded Mar 6, 2026
From: VERSITECH LIMITED
To: UNIVERSITY OF HONG KONG VERSITECH LIMITED
Reel/Frame 075020/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: KAO, YI TSUN RICHARD; YAM, HIN CHEUNG BILL; GAO, PENG; IU, HO TING
To: VERSITECH LIMITED
Reel/Frame 061520/0903 →